Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study

BACKGROUND: Although trastuzumab (T) represents the standard of care for the adjuvant treatment of HER2‐positive early‐stage breast cancer, contrasting results are available about the cardiac toxicity associated to its use. We conducted a multiregional population‐based cohort investigation aimed to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Franchi, Matteo, Trama, Annalisa, Merlo, Ivan, Minicozzi, Pamela, Tarantini, Luigi, Garau, Donatella, Kirchmayer, Ursula, Di Martino, Mirko, Romero, Marilena, De Carlo, Ilenia, Scondotto, Salvatore, Apolone, Giovanni, Corrao, Giovanni
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543336/
https://ncbi.nlm.nih.gov/pubmed/32770690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0216
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars